dadstimeon Posted July 2, 2005 Share Posted July 2, 2005 be Presented at 11th World Conference on Lung Cancer http://biz.yahoo.com/prnews/050630/nyth015.html?.v=14 Press Release Source: Imedex®, Inc. Nearly 1,500 Abstracts Featuring Groundbreaking Research to be Presented at 11th World Conference on Lung Cancer Thursday June 30, 6:35 am ET Six Best - Including Phase III Studies on New Drug Therapies and Longitudinal Study On Quality of Life for Long Term Survivors - Featured in Presidential Symposium ALPHARETTA, Ga., June 30 /PRNewswire/ -- Nearly 1,500 abstracts featuring groundbreaking research will be presented at the 11th World Conference on Lung Cancer in Barcelona, Spain from July 2-6, 2005. Sponsored by the International Association for the Study of Lung Cancer (IASLC), the conference will be attended by more than 4,500 lung cancer specialists from a wide range of disciplines. Lung cancer currently accounts for 12% of all cancers worldwide and nearly a third of all cancer related deaths. "This is a critical moment for those of us working in the lung cancer field, both in disease prevention and disease management," said Dr. Paul A. Bunn Jr., Executive Director of The International Association for the Study of Lung Cancer (IASLC). "New achievements in early detection of lung cancer and multidisciplinary approaches, even in early stages, are coming to the foreground while Pharmacogenomic research and clinical trials, including genetic assessment and multidisciplinary approaches, are advancing at a great pace." From new therapies and drugs that are receiving attention for promising results to long-term studies on quality of life, the top six abstracts will be presented as part of the Presidential Symposium (July 5) and include: -- A study on the efficacy of Radiofrequency Ablation (RFS) of focal malignancy in the treatment of primitive and secondary neoplasms -- A prospective study to compare the performance of remediastinoscopy versus PET-CT in detecting residual mediastinal disease after induction therapy -- The final results of a large randomized phase III trial demonstrating a survival benefit of vinorelbine-cisplatin as adjuvant chemotherapy for completely resected non small cell lung cancer patients -- A placebo-controlled Phase III trial to investigate the survival benefit of 2nd/3rd line gefitnib monotherapy in patients with advanced non small cell lung cancer -- A randomized trial to determine the best treatment -- radical surgery versus thoracic radiotherapy -- in patients with stage IIIA-N2 non small cell lung cancer after response to induction chemotherapy -- A longitudinal study to assess quality of life in long-term cancer survivors Added Dr. Rafael Rosell, Chief of the Medical Oncology Service and Scientific Director for Oncology at the Institut Catala d'Oncologia, Hospital Germans Trias i Pujol in Badalona, Barcelona, Spain and president of the conference, "The data that will be presented in the Presidential Symposium is an overview of the best research being done across the globe and is a testament to the superior researchers, clinicians and medical professionals working in the field today." All of the accepted abstracts have been published in a supplement to Lung Cancer, a high-quality, quarterly international journal published by the IASLC. About the World Conference on Lung Cancer The 11th World Conference on Lung Cancer in Barcelona, Spain from July 3-6, 2005 is sponsored by the International Association for the Study of Lung Cancer (IASLC). More than 4,500 participants are expected for the scientific gathering. More than 200 lung cancer specialists from a range of disciplines will participate in the scientific program and their presentations will provide delegates with information on the latest developments in basic and clinical research. In addition, a special Fellows Day, July 2, 2005, will provide educational and professional opportunities for students and those in the early stages of their careers. The conference will be held at the International Convention Center of Barcelona. Conference information is available online at http://www.2005worldlungcancer.org or by contacting Imedex, the conference organizer. About the IASLC Founded in 1972, the IASLC is an international organization with more than 1150 members in 53 countries. The purpose of the Association is to promote the study of the etiology, the epidemiology, the prevention, the diagnosis, the treatment and all other aspects of lung cancer and to disseminate information about lung cancer to the members of the Association, to the medical community at large, and to the public. Website: http://www.iaslc.org. About ImedexÂ®, Inc. ImedexÂ®, Inc. (http://www.imedex.com) has a twenty year history of providing full service, multi-accredited continuing education for the medical community. Imedex is a leader in strategic and continued outreach to specialists and other health care professionals with a demonstrated return on educational investment. Imedex core competencies include the conception of high-quality scientific programs, development of faculty, deep knowledge of current and relevant medical topics in key therapeutic areas, and precise execution of planned events. For additional information, visit Imedex at http://www.imedex.com. education is the best medicineÂ® Source: Imedex®, Inc. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.